UPLC Liquid Chromatograph Mass Spectrometer

描述(由申请者提供)：我们申请资金购买岛津LCMS-2020和UFLC XR，用于哥伦比亚大学医学中心(CUMC)的协作核心设施(有机化学核心中心或OCCC)。有机化学核心中心，包括其LC/MS设施，是唯一提供定制有机合成、药物发现和仪器分析服务的实体，以支持美国国立卫生研究院资助的CUMC生物医学研究。该仪器将取代已有10年历史的岛津液色谱质谱计，后者一直面临频繁的与年龄相关和与年龄相适应的困难。如果不及时更新新的文书，就会危及大量赠款的进展。这项新工具将使NIH能够继续支持25笔(平均每年)的个人赠款。该仪器的主要“动手”用户将是该中心的合成有机化学家，他们通过CUMC的生物医学研究人员的合作努力来制造和表征小分子。该仪器的最终受益者，也就是指导合成化学家的研究人员，从几十年来由NIH资助的成熟的研究人员，到寻求NIH首次支持的年轻教职员工。他们的研究依赖于该中心LC/MS设施所特有的小分子，以研究与各种疾病状态相关的生物过程，如阿尔茨海默病、精神分裂症、前列腺癌和乳腺癌、心力衰竭、糖尿病、慢性疼痛和肺气肿等。该仪器将由医学系实验治疗学部内的有机化学核心设施和哥伦比亚大学医学中心(CUMC)欧文临床和转化研究所(CUMC)内的生物标记物核心设施共同管理。

DESCRIPTION (provided by applicant): We request funds to purchase a Shimadzu LCMS-2020 with UFLC XR for a collaborative core facility (The Organic Chemistry Core Center or OCCC) at the Columbia University Medical Center (CUMC). The Organic Chemistry Core Center, including its LC/MS facility, is the only entity offering custom organic synthesis, drug discovery, and instrumental analysis services in support of NIH-funded biomedical research at the CUMC. The instrument will replace a 10-year-old 2010A Shimadzu liquid chromatograph mass spectrometer, which has been experiencing frequent age-related and age-appropriate difficulties. Lack of timely upgrade to a new instrument endangers progress of a large number of grants. The new instrument will enable the continuing support for 25 (a yearly average) individual NIH grants. The primary "hands-on" users of the instrument will be synthetic organic chemists of the Center that make and characterize small molecules directed through a collaborative effort by biomedical researchers at the CUMC. The end beneficiaries of the instrument, that is, the researchers directing the synthetic chemists, span the spectrum from well-established investigators, funded by the NIH for decades, to young faculty, seeking first-time support from the NIH. Their research relies on small molecules characterized by the Center's LC/MS facility to study biological processes associated with various disease states, such as Alzheimer's Disease, schizophrenia, prostate and breast cancer, heart failure, diabetes, chronic pain, and emphysema, among others. The instrument will be co-managed by the Organic Chemistry Core Facility within the Division of Experimental Therapeutics of the Department of Medicine and the Biomarkers Core Facility within the Irving Institute for Clinical and Translational Research at the Columbia University Medical Center (CUMC).